Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
D000362:Agar / Q000737:chemistry; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D015820:Cadherins / Q000096:biosynthesis; D018797:Cell Cycle Proteins / Q000096:biosynthesis; D002455:Cell Division; D045744:Cell Line, Tumor; D002843:Chromatin / Q000378:metabolism; D019938:Cyclin D1 / Q000096:biosynthesis; D056742:Cyclin D2; D050759:Cyclin-Dependent Kinase Inhibitor p21; D050760:Cyclin-Dependent Kinase Inhibitor p27; D016213:Cyclins / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D056572:Histone Deacetylase Inhibitors; D006657:Histones / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D020287:In Situ Nick-End Labeling; D051379:Mice; D008819:Mice, Nude; D011233:Precipitin Tests; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D016196:S Phase; D012978:Sodium Oxybate / Q000494:pharmacology; D013997:Time Factors; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis; D014635:Valproic Acid / Q000494:pharmacology; D000077337:Vorinostat
D000970:Antineoplastic Agents; C080336:CCND2 protein, human; C493956:CDKN1A protein, human; D015820:Cadherins; C486196:Ccnd2 protein, mouse; C493957:Cdkn1a protein, mouse; C493961:Cdkn1b protein, mouse; D018797:Cell Cycle Proteins; D002843:Chromatin; D056742:Cyclin D2; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D006877:Hydroxamic Acids; D019253:Proto-Oncogene Proteins c-bcl-2; D025521:Tumor Suppressor Proteins; D019938:Cyclin D1; D050760:Cyclin-Dependent Kinase Inhibitor p27; C012589:trichostatin A; D000077337:Vorinostat; D014635:Valproic Acid; D012978:Sodium Oxybate; D000362:Agar